COMP <GO>
DGX vs GH // EV/EBITDA & P/E VALUATION
Quest Diagnostics Incorporated (NYSE) VS. Guardant Health Inc. (NASDAQ) • 15-METRIC TALLY: DGX 9
— GH 4
■ METRIC PARITY
LAST: $251.82 (-0.43%) • MKT CAP: $27.83B
valuation
16.3x
LAST: $178.80 (-3.51%) • MKT CAP: $24.87B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DGX VS. GH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DGX | GH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 33.20% | 64.50% | -31.30 | GH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 10.30% | -17.40% | +27.70 | DGX | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 16.3x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 4.88% | -0.94% | +5.82 | DGX | /fcf-yield <GO> |
| Operating Margin | 14.10% | -44.50% | +58.60 | DGX | /operating-margins <GO> |
| Net Profit Margin | 9.00% | -42.40% | +51.40 | DGX | /net-margins <GO> |
| Revenue Growth (YoY) | 11.80% | 32.90% | -21.10 | GH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.27% | 0.00% | +1.27 | DGX | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.01 | 5.44 | -1.43 | GH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 6/9 | +2.00 | DGX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 69.4 | 62.0 | +7.40 | DGX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.01 | 0.87 | +0.14 | DGX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.1x | 19.0x | +7.10 | GH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $27.83B | $24.87B | $2.96B | DGX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DGX REV | GH REV | DGX GROSS % | GH GROSS % | DGX FCF | GH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $11.04B | $982.0M | 33.2% | 64.5% | $1.36B | -$233.1M |
| FY 2024 | $9.87B | $739.0M | 32.9% | 60.8% | $909.0M | -$274.9M |
| FY 2023 | $9.25B | $563.9M | — | — | $855.7M | -$350.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DGX // BETA 1.01
GH // BETA 0.87